We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Doxil Shortages Continue to Dog J&J; Full OTC Recovery in 2013 Unlikely
Doxil Shortages Continue to Dog J&J; Full OTC Recovery in 2013 Unlikely
February 4, 2013
Johnson & Johnson subsidiary Janssen Products continues to struggle to provide dependable access to its cancer drug Doxil due to ongoing supplier issues.